ColoAlert colorectal screening test receives approval in Switzerland

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ColoAlert, a non-invasive colorectal cancer screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. The test is designed to detect CRC tumor DNA and other biomarkers with high sensitivity in stool samples.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login